GSK plc
GSK
$38.40
$0.441.16%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.23B | 40.10B | 39.71B | 39.60B | 38.64B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.23B | 40.10B | 39.71B | 39.60B | 38.64B |
| Cost of Revenue | 11.30B | 11.31B | 10.96B | 10.77B | 10.55B |
| Gross Profit | 28.93B | 28.80B | 28.75B | 28.83B | 28.09B |
| SG&A Expenses | 13.87B | 13.79B | 13.67B | 11.57B | 11.38B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -586.49M | -551.26M | -1.20B | -1.61B | -1.74B |
| Total Operating Expenses | 32.38B | 32.32B | 31.09B | 28.34B | 27.67B |
| Operating Income | 7.85B | 7.79B | 8.62B | 11.26B | 10.97B |
| Income Before Tax | 5.35B | 4.41B | 4.16B | 6.34B | 6.94B |
| Income Tax Expenses | 742.23M | 666.49M | 563.49M | 890.19M | 952.16M |
| Earnings from Continuing Operations | 4.60K | 3.74K | 3.59K | 5.45K | 5.99K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -623.14M | -481.12M | -429.32M | -357.89M | -344.09M |
| Net Income | 3.98B | 3.26B | 3.17B | 5.09B | 5.65B |
| EBIT | 7.85B | 7.79B | 8.62B | 11.26B | 10.97B |
| EBITDA | 11.61B | 11.21B | 11.65B | 13.78B | 13.25B |
| EPS Basic | 0.97 | 0.80 | 0.78 | 1.25 | 1.39 |
| Normalized Basic EPS | 0.95 | 0.97 | 1.10 | 1.52 | 1.48 |
| EPS Diluted | 0.96 | 0.79 | 0.77 | 1.24 | 1.38 |
| Normalized Diluted EPS | 0.94 | 0.96 | 1.09 | 1.50 | 1.46 |
| Average Basic Shares Outstanding | 16.33B | 16.31B | 16.28B | 16.26B | 16.23B |
| Average Diluted Shares Outstanding | 16.55B | 16.52B | 16.49B | 16.46B | 16.43B |
| Dividend Per Share | 0.79 | 0.78 | 0.77 | 0.76 | 0.74 |
| Payout Ratio | 79.74% | 95.77% | 96.19% | 58.22% | 50.30% |